Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …”

Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …”

Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …”

Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …”

Example of skyline query for proteins. by Rizka Fatriani (17485787)

“…Molecular docking results between PPARG and EP300 with the ten active compounds showed a binding affinity value of ≤ -5.0 kcal/mol in all dockings, indicating strong binding. …”

Top 10 pathways with the lowest p-value. by Rizka Fatriani (17485787)

“…Molecular docking results between PPARG and EP300 with the ten active compounds showed a binding affinity value of ≤ -5.0 kcal/mol in all dockings, indicating strong binding. …”

Pseudocode of block-nested loop (BNL). by Rizka Fatriani (17485787)

“…Molecular docking results between PPARG and EP300 with the ten active compounds showed a binding affinity value of ≤ -5.0 kcal/mol in all dockings, indicating strong binding. …”

Top 10 gene ontologies with the lowest p-value. by Rizka Fatriani (17485787)

“…Molecular docking results between PPARG and EP300 with the ten active compounds showed a binding affinity value of ≤ -5.0 kcal/mol in all dockings, indicating strong binding. …”

Fig 5 - by Héctor Raúl Olivares-Sánchez (13014866)

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”

MBIC50 and MBEC50 values (µg/mL) of synthesized 1,2,3,5-tetrazine derivatives against bacteria pathogen strains. by Jean Paul Dzoyem (6424445)

Subjects:

Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…Outpatient visit frequency also significantly declined from 11.5 ± 4.3 visits in the year before surgery to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g004" target="_blank">Fig 4</a>).…”

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Mean frequency of the cultural trait <i>T</i> in the population when <i>T</i> decreases fertility. by Laurel Fogarty (143721)

Difference in mean Capability scores by age (≥55 vs. <55 years) among people with TB. by Kevin Guzman (16474985)

Difference in mean Motivation scores by age (≥55 vs. <55 years) among people with TB. by Kevin Guzman (16474985)

Difference in mean Opportunity scores by age (≥55 vs. <55 years) among people with TB. by Kevin Guzman (16474985)

Inhibition of ABCG2 decreases SP cells, but not sphere-forming ability. by Noriko Kawai (6694010)

Changes in mean serum creatine kinase (CK) levels with age. by UnKyu Yun (11177542)